WO2002033099A3 - Human kinases - Google Patents

Human kinases Download PDF

Info

Publication number
WO2002033099A3
WO2002033099A3 PCT/US2001/047728 US0147728W WO0233099A3 WO 2002033099 A3 WO2002033099 A3 WO 2002033099A3 US 0147728 W US0147728 W US 0147728W WO 0233099 A3 WO0233099 A3 WO 0233099A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkin
provides
human kinases
human
kinases
Prior art date
Application number
PCT/US2001/047728
Other languages
French (fr)
Other versions
WO2002033099A2 (en
Inventor
Rajagopal Gururajan
Mariah R Baughn
Narinder K Chawla
Original Assignee
Incyte Genomics Inc
Rajagopal Gururajan
Mariah R Baughn
Narinder K Chawla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Rajagopal Gururajan, Mariah R Baughn, Narinder K Chawla filed Critical Incyte Genomics Inc
Priority to CA002425963A priority Critical patent/CA2425963A1/en
Priority to US10/415,011 priority patent/US20040053394A1/en
Priority to JP2002536068A priority patent/JP2004537258A/en
Priority to EP01987811A priority patent/EP1373517A2/en
Priority to AU2002227352A priority patent/AU2002227352A1/en
Publication of WO2002033099A2 publication Critical patent/WO2002033099A2/en
Publication of WO2002033099A3 publication Critical patent/WO2002033099A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides human human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.
PCT/US2001/047728 2000-10-20 2001-10-20 Human kinases WO2002033099A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002425963A CA2425963A1 (en) 2000-10-20 2001-10-20 Human kinases
US10/415,011 US20040053394A1 (en) 2001-10-20 2001-10-20 Human kinases
JP2002536068A JP2004537258A (en) 2000-10-20 2001-10-20 Human kinase
EP01987811A EP1373517A2 (en) 2000-10-20 2001-10-20 Human kinases
AU2002227352A AU2002227352A1 (en) 2000-10-20 2001-10-20 Human kinases

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US24241000P 2000-10-20 2000-10-20
US60/242,410 2000-10-20
US24406800P 2000-10-27 2000-10-27
US60/244,068 2000-10-27
US24570800P 2000-11-03 2000-11-03
US60/245,708 2000-11-03
US24767200P 2000-11-09 2000-11-09
US60/247,672 2000-11-09
US24956500P 2000-11-16 2000-11-16
US60/249,565 2000-11-16
US25273000P 2000-11-22 2000-11-22
US60/252,730 2000-11-22
US25080700P 2000-12-01 2000-12-01
US60/250,807 2000-12-01

Publications (2)

Publication Number Publication Date
WO2002033099A2 WO2002033099A2 (en) 2002-04-25
WO2002033099A3 true WO2002033099A3 (en) 2003-10-09

Family

ID=27569438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047728 WO2002033099A2 (en) 2000-10-20 2001-10-20 Human kinases

Country Status (5)

Country Link
EP (1) EP1373517A2 (en)
JP (1) JP2004537258A (en)
AU (1) AU2002227352A1 (en)
CA (1) CA2425963A1 (en)
WO (1) WO2002033099A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001753B2 (en) 2001-02-15 2006-02-21 Millennium Pharmaceuticals, Inc. 59079 and 12599, protein kinase family members and uses therefor
US6638745B1 (en) * 2001-03-13 2003-10-28 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7148050B2 (en) 2001-03-16 2006-12-12 Bayer Healthcare Ag Regulation of human protein kinase-like protein
AU2003206854A1 (en) * 2002-02-06 2003-09-02 Developgen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
US7326781B2 (en) 2002-04-12 2008-02-05 Bristol-Myers Squibb Company Polynucleotides encoding the human citron kinase polypeptide, BMSNKC—0020/0021
GB0220770D0 (en) * 2002-09-06 2002-10-16 Ares Trading Sa Proteins
DK1644493T3 (en) * 2003-06-27 2010-09-13 Axikin Pharmaceuticals Inc Regulation of a kinase, 'regulated in COPD kinase' (RC kinase)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017189A2 (en) * 1993-01-21 1994-08-04 The Salk Institute For Biological Studies Protein kinases
WO2001038503A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Novel human protein kinases and protein kinase-like enzymes
WO2001098342A1 (en) * 2000-06-22 2001-12-27 Smithkline Beecham Corporation Novel compounds
WO2002014355A2 (en) * 2000-08-11 2002-02-21 Merck Patent Gmbh Novel mitogen activated kinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017189A2 (en) * 1993-01-21 1994-08-04 The Salk Institute For Biological Studies Protein kinases
WO2001038503A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Novel human protein kinases and protein kinase-like enzymes
WO2001098342A1 (en) * 2000-06-22 2001-12-27 Smithkline Beecham Corporation Novel compounds
WO2002014355A2 (en) * 2000-08-11 2002-02-21 Merck Patent Gmbh Novel mitogen activated kinase

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHUNG CHANG Y ET AL: "A novel, putative MEK kinase controls developmental timing and spatial patterning in Dictyostelium and is regulated by ubiquitin-mediated protein degradation.", GENES & DEVELOPMENT, vol. 12, no. 22, 15 November 1998 (1998-11-15), pages 3564 - 3578, XP002246600, ISSN: 0890-9369 *
DATABASE EMBL [online] 1 March 2001 (2001-03-01), "Hypothetical protein FLJ23074", XP002246601, Database accession no. Q9H5T2 *
FISH KIMBERLY J ET AL: "Isolation and Characterization of Human Casein Kinase I-epsilon (CKI), a Novel Member of the CKI Gene Family.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 25, 1995, pages 14875 - 14883, XP002177865, ISSN: 0021-9258 *
GRAVES D J: "Powerful tools for genetic analysis come of age", TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 3, March 1999 (1999-03-01), pages 127 - 134, XP004157733, ISSN: 0167-7799 *
GREEN C L ET AL: "Identification of four alternatively spliced isoforms of chicken casein kinase I alpha that are all expressed in diverse cell types", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 216, no. 1, August 1998 (1998-08-01), pages 189 - 195, XP004149296, ISSN: 0378-1119 *
PULGAR VICTOR ET AL: "The recombinant alpha isoform of protein kinase CK1 from Xenopus laevis can phosphorylate tyrosine in synthetic substrates.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 242, no. 3, 1996, pages 519 - 528, XP001119751, ISSN: 0014-2956 *
ROWLES J ET AL: "PURIFICATION OF CASEIN KINASE I AND ISOLATION OF CDNAS ENCODING MULTIPLE CASEIN KINASE I-LIKE ENZYMES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 21, 1991, pages 9548 - 9552, XP001119756, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2004537258A (en) 2004-12-16
WO2002033099A2 (en) 2002-04-25
EP1373517A2 (en) 2004-01-02
CA2425963A1 (en) 2002-04-25
AU2002227352A1 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
WO2001098468A3 (en) Proteases
WO2003052075A3 (en) Enzymes
WO2001096547A3 (en) Human kinases
WO2001060991A3 (en) Human kinases
WO2002018557A3 (en) Human kinases
WO2002008396A3 (en) Human proteases
WO2003033680A3 (en) Kinases and phosphatases
WO2002083709A3 (en) Kinases and phosphatases
WO2001046397A3 (en) Human kinases
WO2001090334A3 (en) Drug metabolizing enzymes
WO2001051638A3 (en) Drug metabolizing enzymes
WO2002004612A3 (en) Drug metabolizing enzymes
WO2001072777A3 (en) Human transcription factors
WO2002038744A3 (en) Proteases
WO2003042357A3 (en) Enzymes
WO2001098471A8 (en) Human phosphodiesterases
WO2002026950A3 (en) Transferases
WO2001096546A3 (en) Protein phosphatases
WO2001071004A3 (en) Proteases
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2002010363A3 (en) Protein phosphatases
WO2002033099A3 (en) Human kinases
WO2001081555A3 (en) Human kinases
WO2002020736A3 (en) Proteases
WO2001079468A3 (en) Drug metabolizing enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2425963

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002536068

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10415011

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001987811

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001987811

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001987811

Country of ref document: EP